Lumos Pharma — NewLink Genetics — FY2017 Earnings Presentation
9 slides from Lumos Pharma's earnings presentation, Mar 1, 2018
Slide 1: Fourth Quarter and Year-End 2017 Financial Results
NewLink Genetics Corporation Nasdaq: NLNK March 1, 2018 Fourth Quarter and Year-End 2017 Financial Results
Slide 2: Agenda
Agenda 2 Introduction Jack Henneman, Executive Vice President & CFO IDO Pathway Program Developments & Outlook Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates & Guidance on Timing of Data Eugene P. Kennedy, M.D., Chief Medical Officer Fourth Quarter and Year-End 2017 Financial
Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward- looking statements,
Slide 4: 2017 Highlights
2017 Highlights Presented updated Phase 2 data of indoximod plus pembrolizumab indicating encouraging overall and complete responses and progression-free survival Commenced dose determination portion of Indigo301, a pivotal Phase 3 trial for patients with advanced melanoma Entered into a colla
Slide 5: 2018 Highlights
2018 Highlights Initiate randomization of Indigo301, a pivotal Phase 3 in advanced melanoma in Q2-Q3 2018 Full Phase 2 results of indoximod plus checkpoint inhibitors in metastatic melanoma 1H:2018 Initiate Indigo201, a randomized Phase 2 in metastatic pancreatic cancer in 1H:2018 Full Phase
Slide 6: Indigo301 Phase 3 Trial Design in Advanced Melanoma
6 • Adults ≥18 years of age with unresectable stage III or IV advanced melanoma • No prior melanoma therapy, except BRAF/MEK inhibitor Prior adjuvant or neoadjuvant therapy ≥4 weeks before randomization Prior adjuvant immunotherapy (no relapse during treatment or ≤6 months of treatment discontinuati
Slide 7: Financial Position
Financial Position YE 2017 Cash and Equivalents $158.7 million Debt ~$0.3 million YE 2018 Cash (Projected)1 ~$75 million Forecast Quarterly Cash Use ~$20-22 million Shares Outstanding as of December 31,2017 37.1 million 7 1 Excludes projections of proceeds, if any, from potential future financings F
Slide 8: Key Takeaways for 2018
NewLink Genetics Initiation of two key randomized trials with indoximod plus checkpoint inhibition – Indigo301 for patients with advanced melanoma – Indigo201 in collaboration with AstraZeneca for patients with metastatic pancreatic cancer Presentation of results from two Phase 2 trials – Full P
Slide 9: Q & A
9 Q & A